Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours

被引:11
作者
Mao, Rui [1 ]
Hussein, Mohamed S. [1 ]
He, Yukai [1 ,2 ]
机构
[1] Georgia Canc Ctr, Augusta, GA 30912 USA
[2] Augusta Univ, Med Coll Georgia, Dept Med, Augusta, GA 30912 USA
来源
EXPERT REVIEWS IN MOLECULAR MEDICINE | 2022年 / 24卷
关键词
Adoptive cell transfer; chimeric antigen receptor; T cell engineering; tumour immunotherapy; ANTITUMOR-ACTIVITY; B-CELL; PHASE-I; CARCINOEMBRYONIC ANTIGEN; MONOCLONAL-ANTIBODY; 4-1BB COSTIMULATION; ADOPTIVE TRANSFER; BINDING DOMAINS; TARGET-CELLS; CAR;
D O I
10.1017/erm.2021.32
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this article, we reviewed the current literature studies and our understanding of the parameters that affect the chimeric antigen receptor T cells (CAR-T's) activation, effector function, in vivo persistence, and antitumour effects. These factors include T cell subsets and their differentiation stages, the components of chimeric antigen receptors (CAR) design, the expression promoters and delivery vectors, and the CAR-T production process. The CAR signalling and CAR-T activation were also studied in comparison to TCR. The last section of the review gave special consideration of CAR design for solid tumours, focusing on strategies to improve CAR-T tumour infiltration and survival in the hostile tumour microenvironment. With several hundred clinical trials undergoing worldwide, the pace of CAR-T immunotherapy moves from bench to bedside is unprecedented. We hope that the article will provide readers a clear and comprehensive view of this rapidly evolving field and will help scientists and physician to design effective CAR-Ts immunotherapy for solid tumours.
引用
收藏
页数:15
相关论文
共 50 条
  • [11] Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies
    El-Khazragy, Nashwa
    Ghozy, Sherief
    Emad, Passant
    Mourad, Mariam
    Razza, Diaaeldeen
    Farouk, Yasmeen K.
    Mohamed, Nermeen A.
    Ahmed, Mohamed K.
    Youssef, Tarek
    Bahnasawy, Youssef M.
    Elmasery, Shereen
    IMMUNOTHERAPY, 2020, 12 (18) : 1341 - 1357
  • [12] Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
    Yilmaz, Ahmet
    Cui, Hanwei
    Caligiuri, Michael A.
    Yu, Jianhua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [13] Chimeric Antigen Receptor T Cells for Cancer Immunotherapy
    Curran, Kevin J.
    Brentjens, Renier J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) : 1703 - +
  • [14] Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
    Hillerdal, Victoria
    Essand, Magnus
    BIODRUGS, 2015, 29 (02) : 75 - 89
  • [15] Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells
    Alrifai, Doraid
    Sarker, Debashis
    Maher, John
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2016, 38 (01) : 50 - 60
  • [16] Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy
    Chu Lin
    Jun Zhang
    Science China Life Sciences, 2019, 62 : 633 - 639
  • [17] Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy
    Chu Lin
    Jun Zhang
    Science China(Life Sciences) , 2019, (05) : 633 - 639
  • [18] RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
    Harrer, Dennis C.
    Simon, Bianca
    Fujii, Shin-ichiro
    Shimizu, Kanako
    Uslu, Ugur
    Schuler, Gerold
    Gerer, Kerstin F.
    Hoyer, Stefanie
    Dorrie, Jan
    Schaft, Niels
    BMC CANCER, 2017, 17
  • [19] Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy
    Chaudhry, Kajal
    Dowlati, Ehsan
    Bollard, Catherine M.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (06) : 643 - 659
  • [20] Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
    Li, Feng
    Zhang, Tengfei
    Cao, Ling
    Zhang, Yi
    CURRENT STEM CELL RESEARCH & THERAPY, 2018, 13 (05) : 327 - 335